Teva Prepares To Launch LAI Risperidone After US Approval

MedinCell-Partnered Schizophrenia Treatment Uzedy Has Now Been Approved By US FDA

 
• By Dave Wallace

Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.

FDA approved stamp logo, blue
The FDA has approved Teva and MedinCell’s LAI risperidone as Uzedy • Source: Shutterstock

More from Products

More from Generics Bulletin